55 related articles for article (PubMed ID: 29753690)
1. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
[No Abstract] [Full Text] [Related]
2. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Arora N; Gupta A; Sadeghi N
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
[TBL] [Abstract][Full Text] [Related]
3. [Newest Advances in Diagnosis and Treatment of Plasmablastic Lymphoma --Review].
Peng HL; Yang HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1594-1598. PubMed ID: 37846723
[TBL] [Abstract][Full Text] [Related]
4. Plasmablastic lymphoma: better refine prognosis.
Coppo P; Ricard L
Blood; 2024 Jan; 143(2):101-102. PubMed ID: 38206643
[No Abstract] [Full Text] [Related]
5. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
6. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
7. Plasmablastic lymphoma: current perspectives.
Lopez A; Abrisqueta P
Blood Lymphat Cancer; 2018; 8():63-70. PubMed ID: 31360094
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features, management, and outcomes of plasmablastic lymphoma: A 10-year experience.
Arora N; Eule C; Gupta A; Li HC; Sadeghi N
Am J Hematol; 2019 May; 94(5):E127-E129. PubMed ID: 30734351
[No Abstract] [Full Text] [Related]
9. Clinical Features of Plasmablastic Lymphoma: Case Series From an Asian Tertiary Cancer Center and Literature Review.
Yap DRY; Tan GF; Chang EWY; Yang VS; Poon EYL; Somasundaram N; Farid M; Tang T; Tao M; Lim ST; Chan JY
J Hematol; 2020 Sep; 9(3):71-78. PubMed ID: 32855755
[TBL] [Abstract][Full Text] [Related]
10. Survival analysis in treated plasmablastic lymphoma patients: a population-based study.
Florindez JA; Alderuccio JP; Reis IM; Lossos IS
Am J Hematol; 2020 Nov; 95(11):1344-1351. PubMed ID: 32777103
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients.
Witte HM; Hertel N; Merz H; Bernd HW; Bernard V; Stölting S; von Bubnoff N; Feller AC; Gebauer N
Blood Cancer J; 2020 May; 10(5):63. PubMed ID: 32471974
[No Abstract] [Full Text] [Related]
12. Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion.
Yoshihara K; Yoshihara S; Matsuda I; Imado T; Matsuo S; Okada M; Shimizu Y; Hirota S; Fujimori Y
Ann Hematol; 2020 Jun; 99(6):1405-1407. PubMed ID: 32125468
[No Abstract] [Full Text] [Related]
13. Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches.
Chen BJ; Chuang SS
Adv Anat Pathol; 2020 Mar; 27(2):61-74. PubMed ID: 31725418
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review.
Rodrigues-Fernandes CI; de Souza LL; Santos-Costa SFD; Silva AMB; Pontes HAR; Lopes MA; de Almeida OP; Brennan PA; Fonseca FP
J Oral Pathol Med; 2018 Nov; 47(10):915-922. PubMed ID: 29917262
[TBL] [Abstract][Full Text] [Related]
15. The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes.
Makady NF; Ramzy D; Ghaly R; Abdel-Malek RR; Shohdy KS
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e255-e263. PubMed ID: 33419717
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature.
Lee M; Martin BA; Abdulhaq H
Case Rep Hematol; 2022; 2022():8331766. PubMed ID: 35795542
[TBL] [Abstract][Full Text] [Related]
17. Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on Therapy.
Bibas M
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024015. PubMed ID: 38468838
[TBL] [Abstract][Full Text] [Related]
18. Plasmablastic lymphoma: current knowledge and future directions.
Li JW; Peng HL; Zhou XY; Wang JJ
Front Immunol; 2024; 15():1354604. PubMed ID: 38415257
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.
Sabry W; Wu Y; Kodad SG
Curr Oncol; 2022 Jul; 29(7):5042-5053. PubMed ID: 35877259
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
